Advantages

- MMG49-derived CAR-T cells have been administered to patients in a Phase I/II clinical trial
- Potential to leverage the unique properties of MMG49 through integration with next-generation CAR technologies or novel therapeutic formats
- Potential applications beyond multiple myeloma, including inflammatory bowel disease (IBD), may also be explored

Current Stage and Key Data

Current Stage
- MMG49-derived CAR-T cells have been administered to patients with relapsed or refractory multiple myeloma in a Phase I/II clinical trial.
Key Data
- MMG49-derived CAR-T cells demonstrated antitumor activity in an in vivo model of multiple myeloma, with no damage to normal hematopoietic cells observed.
- Clinical trial-related information will be shared under CDA

Partnaring Model

The University of Osaka is seeking corporate partners to advance the clinical development of MMG49 CAR-T. Opportunities to develop other modalities using this antibody, including CAR-NK cells and bispecific antibodies, are also open for discussion. Through technical discussions with the principal investigator, we can provide information on clinical development status and share non-public data where disclosure is permitted, while exploring licensing, collaborative research, and other partnership arrangements.

Background and Technology

Although therapies targeting CD38, BCMA, and other antigens have been developed for multiple myeloma, there remains a need for treatment options based on distinct target recognition strategies for patients with relapsed or refractory disease.
MMG49, a novel proprietary antibody developed by the research team, recognizes an epitope exposed in the active conformation of integrin β7. It shows high reactivity toward myeloma cells, in which integrin β7 is highly expressed and constitutively activated. In contrast, binding to normal β7-positive lymphocytes is barely detectable. Leveraging this recognition profile may enable the development of tumor-targeted therapies that minimize effects on normal cells.

Principal Investigator

Professor. Naoki HOSEN (Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine)

Patents and Publications

Information on related literature is included in the materials. Please click the “Iinterested in this technology? [Download Materials]” button below to download and view the materials.